Teva Pharmaceutical Expects 2024 Adjusted EPS Of $2.30-$2.50 Versus Prior Guidance Of $2.20-$2.50 And Consensus Of $2.34
Portfolio Pulse from Benzinga Newsdesk
Teva Pharmaceutical has updated its 2024 adjusted EPS guidance to a range of $2.30-$2.50, up from the previous range of $2.20-$2.50, and above the consensus estimate of $2.34.
July 31, 2024 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teva Pharmaceutical has raised its 2024 adjusted EPS guidance to $2.30-$2.50, up from the previous range of $2.20-$2.50, and above the consensus estimate of $2.34. This positive revision indicates stronger-than-expected financial performance.
The upward revision of the EPS guidance suggests that Teva Pharmaceutical is expecting better financial performance than previously anticipated. This is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100